News

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]

Data from a cohort of nearly 100 patients with Parkinson disease suggest there are shared nondopaminergic pathogenic mechanisms between depression and postural instability symptoms of the disease.

The professor of neurology at the University of Toronto spoke at the 2022 AES Conference about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]

The director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

A recent congressional investigation report on Biogen’s aducanumab and the FDA’s approval process recommended Biogen to fulfill their responsibility for individuals who rely on their treatments.

Patients with high dysautonomia scores showed significantly slower walking speed, decreased cadence, and shorter stride but increased time than the lower scored group in backward gait.

The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]

After years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.

Results from a prospective study demonstrated a higher visual field defect in patients with neuromyelitis optica spectrum disorder-optic neuritis compared with those who had idiopathic optic neuritis.

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed a subgroup analysis of the FINGERS trial and the clinical utility of the precursor to serum brain-derived neurotrophic factor. [WATCH TIME: 3 minutes]

The case-control study identified numerous motor symptoms and signals that are associated with Parkinson disease diagnosis years after they begin to occur.

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided perspective on the reasons to not solely rely on anti-amyloid treatments to treat Alzheimer disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Over a 12-week trial, females with MS on bupropion demonstrated improvements in sexual satisfaction, sexual desire, vaginal moisture, and orgasm intensity.

These were the most-watched interviews with experts in sleep disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]

These were the most-watched interviews with experts in stroke and brain injury that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in multiple sclerosis in 2022.

In 2022, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

These were the most-watched interviews with experts in neuromuscular disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at the top most-read news in movement disorders in 2022.

These were the most-read FDA approval stories that were part of our coverage in 2022, brought to you as part of NeurologyLive®'s Year in Review.

These were the most-watched interviews with experts in movement disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in neuromuscular disorders in 2022.

The executive director of Banner Alzheimer’s Institute discussed the efforts being done within the field to improve prevention and therapeutics for Alzheimer disease.

These were the most-watched interviews with experts in multiple sclerosis that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in stroke and cerebrovascular disease in 2022.

These were the most-watched episodes of 2022 from our various video series, brought to you as part of NeurologyLive®'s Year in Review.